Craig E. Cole
University of Miami
6 Papers
25 Citations
Craig E. Cole is an academic researcher from University of Miami. The author has contributed to research in topics: Lenalidomide & Non-Hodgkin's lymphoma. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
Peter H. Wiernik,Izidore S. Lossos,Joseph Tuscano,Glen Justice,Julie M. Vose,Craig E. Cole,Wendy Yin Han Lam,Kyle McBride,Kenton Wride,Dennis Pietronigro,Kenichi Takeshita,Annette Ervin-Haynes,Jerome B. Zeldis,Thomas M. Habermann +13 more
TL;DR: Oral lenalidomide monotherapy is active in relapsed or refractory aggressive NHL, with manageable side effects, in a phase II, single-arm, multicenter trial.
402
Assessment of Psychological Distress in Patients Suffering from Hematological Disorders.
Craig E. Cole,Rebecca Ballandby,Jonean E. Schroeder,Jennifer A. Lee,Michelle A. Mathiason,Rasmus T. Hoeg,Wayne A. Bottner,John P. Farnen,Robert Ettinger,Antoinette M. Peters,Janette M. Dawson,Kaye L. Johnston,Ronald S. Go +12 more
TL;DR: Assessment of distress in hematology patients enrolled between July 2006 and December 2006 found no significant difference in levels of reported distress between patients with malignant and non-malignant hematologic disorders.
8
Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.
Peter H. Wiernik,Izidore S. Lossos,Joseph Tuscano,Glen Justice,Julie M. Vose,Craig E. Cole,Kyle McBride,Kenton Wride,Dennis Pietronigro,Kenichi Takeshita,Annette Ervin-Haynes,Jerome B. Zeldis,Thomas M. Habermann +12 more
TL;DR: Tumor burden and host immune competence may determine the response of relapsed/refractory aggressive NHL to lenalidomide monotherapy and absolute lymphocyte count was not selected as a prognostic indicator of response in the multivariate setting.
7
Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: Final results of NHL-001
T. E. Witzig,Peter H. Wiernik,Timothy E. Moore,Craig B. Reeder,Craig E. Cole,Glen Justice,Henry G. Kaplan,M. Voralia,Dennis Pietronigro,Julie M. Vose +9 more
TL;DR: Oral lenalidomide monotherapy produces durable responses with manageable side effects in relapsed or refractory indolent NHL and warrants further investigation in the treatment of indolents NHL.
6
Lenalidomide Response in Relapsed/Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.
Izidore S. Lossos,Peter H. Wiernik,Glen Justice,Joseph Tuscano,Craig E. Cole,Julie M. Vose,Dennis Pietronigro,Kenichi Takeshita,Annette Ervin-Haynes,Jerome B. Zeldis,Thomas M. Habermann +10 more
TL;DR: The prognostic factors of tumor burden and time from last dose of rituximab appear to identify relapsed/refractory DLBCL patients with a high likelihood of response to lenalidomide oral monotherapy.
5